- Executive branch pressure influences the FDA to implement strong regulatory crackdowns.
- The U.S. biotech industry is concerned that excessive and slow bureaucratic regulation is dulling its competitive edge.
- The US biotech industry is facing unprecedented pressure from growing Chinese competition, leading to government actions like the Biosecure Act and tariffs on biological products.
U.S. Mandate Restricts Federal Procurement from PRC Biotech Firms
What happened
The U.S. BIOSECURE Act, enacted as part of the FY2026 National Defense Authorization Act, restricts U.S. federal procurement and funding from certain PRC biotechnology firms. The Office of Management and Budget was directed to publish and maintain an expanded list of these 'biotechnology companies of concern.' A report identified over 800 PRC-based biotech companies linked to military, intelligence, and internal security institutions, including more than 350 suppliers to the People's Liberation Army.
From prnewswire.com
Why it matters
The law targets firms identified as posing risks to sensitive genomic data and national security. This action limits the ability of U.S. federal agencies to contract with or fund specific PRC biotech companies, impacting their market access in the U.S.
The U.S. biotech industry is facing growing competition from China, leading to government actions like the Biosecure Act and tariffs on biological products.
From prnewswire.com
Who's involved
- Office of Management and BudgetAgency directed to publish and maintain the expanded list of restricted firms.
- BGI GroupA PRC-based genomics company that falls under the scope of the restrictions.
- People’s Liberation ArmyThe principal military force of the People's Republic of China whose suppliers are identified.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BGI GroupSpeculative
BGI Group might face reduced revenue due to restrictions on U.S. federal procurement and funding.
- ChinaSpeculative
Biotech companies in China might face restrictions on their ability to participate in U.S. federal contracts.
- People’s Liberation ArmySpeculative
The People's Liberation Army might need to adjust its procurement strategies for biotech supplies.
Keep exploring
Part of
The US biotech industry is facing unprecedented pressure from growing Chinese competition, leading to government actions like the Biosecure Act and tariffs on biological products. All 1 developmentsWithin Executive branch pressure influences the FDA to implement strong regulatory crackdowns.
The entities involved
-
Office of Management and Budget
agency that prepares and evaluates the President of the United States' annual budget to Congress
-
BGI Group
Chinese life science group that operates multiple research labs and entities in the field of genomics, healthcare, precision medicine, and more
Nothing else this week.